SOURCE: Kantar Health

Kantar Health

July 07, 2011 04:05 ET

Kantar Health France Appoints Dr. Oria Madi Post-Approval and Non-Interventional Studies Director

NEW YORK, NY--(Marketwire - Jul 7, 2011) - Kantar Health, a leading healthcare-focused global consultancy and marketing insights company, has appointed Dr. Oria Madi as Post-Approval and Non-Interventional Studies Director. Dr. Madi will be in charge of growing Kantar Health France's expertise in non-interventional and pharmacoepidemiological studies and will work closely with Dr. Michel Murino, CEO of Kantar Health France.

A specialist in rheumatology, Dr. Madi worked as a private practitioner before joining the pharmaceutical industry. She has held different positions at Procter & Gamble, Pfizer, Sanofi and GSK. During her career, she has had the opportunity to launch a number of molecules and to develop her expertise in post-approval and non-interventional studies. After earning a Business Consulting degree at ESCP, Dr. Madi started a consultancy for the pharmaceutical industry, which she developed over the next five years.

About Kantar Health France
Kantar Health France supports the strategic and operational decisions of its customers within the pharmaceutical industry, committees of experts, learned societies, healthcare facilities, institutions and patient organizations. We conduct more than 500 studies per year, many of them published in scientific journals.

About Kantar Health (
As experts in pharmaceutical and biotechnology consulting and market research, Kantar Health offers unique insights and products that deliver proven results for marketing insights, brand marketing, business development and health economics and outcomes professionals, including:

  • The greatest breadth and depth of epidemiology information in the world, spanning patient-reported outcomes and patient care by country, therapy area, specialist -- or whatever combination of data you require
  • Unmatched experience in the complex oncology market that encompasses business development, clinical management, emerging technologies, marketing and sales, payers and providers, reimbursement and strategic and product planning
  • A unique global source of KOLs for multiple therapy areas

Kantar Health's team combines doctorate-level scientific expertise with strong business know-how, ensuring that solutions are both evidence-based and commercially focused. We offer a wide range of expertise in emerging as well as established markets, spanning the product life cycle from product portfolio management to licensing, market access to brand and reputation management, detailing to clinical research, patient outcomes and sales force effectiveness to health and safety. And as part of WPP, the largest marketing agency in the world, Kantar Health can leverage the power of the global group with shared offline and online research methodologies but remain culturally specific and nimble. Kantar Health focuses on getting you the best return.

Contact Information